当前位置：药药网 / 医药文献 /制药提价与抑制仿制药方式(本栏目收费,不能显示细节,电话13136136841)
关键字：
类型：
下载页码(大于1,小于132)：
制药提价与抑制仿制药方式 472条(本栏目收费,不能显示细节,电话13136136841)
See also Generation 2.0; Generation 3.0;
pay- for- delay; reverse payment schemes
Generation 2.0 strategies, 24, 65
24 65
See alsoGeneration 1.0 strategies; Generation 3.0
strategies; pay- for- delay
acceleration contract clauses, 57,59
57 59
boy scout contract clauses, 24, 59,61, 137
24 59 61 137
diminishment of pay- for- delay deals and, 66
66
FTC v. Actavis and, 65
65
In re Lipitor case of Pfizer v. Ranbaxy, 53,56
53 56
K- Dur case, 50,51, 52
50 51 52
King Drug case of Glaxo v. Teva, 61,65
61 65
no- authorized- generic, non- cash agreements and, 61,64
61 64
non- cash provisions post- Actavis and, 49,50
49 50
Generation 3.0 strategies, 24,25, 65, 137
24 25 65 137
generic delay of Flonase by, 68
68
King Drug case and, 61,65
61 65
Gleevec (leukemia treatment), 6
6
Hatch- Waxman Act (U.S., 1984), 21,23, 25
21 23 25
See also Paragraph IV certification allowance of patent- protected brand- name information for generic research, 26,27
26 27
complexity of as opportunity to hold off generic competition, 23
23
expediting of generic applications before patent expiration, 28
28
forfeiture provision for exclusivity period adjustments, 39,40
39 40
forfeiture provision loopholes in 2003 amendment of, 40
40
generic drug applications and, 21,22, 26,27
21 22 26 27
new drugs non- patent exclusivities and, 32,33
32 33
as new era for generic competition, 21, 33
21 33
Orange book of brand name patents for generic applications, 29,30, 55
29 30 55